(Q40370693)

19 September 2017

title

Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer (English)

1 reference

19 September 2017

main subject

phase I clinical trial

0 references

1 reference

K Anwer

1

1 reference

19 September 2017

M N Barnes

2

1 reference

19 September 2017

J Fewell

3

1 reference

19 September 2017

D H Lewis

4

1 reference

19 September 2017

R D Alvarez

5

1 reference

19 September 2017

publication date

24 December 2009

1 reference

19 September 2017

1 reference

19 September 2017

volume

17

1 reference

19 September 2017

issue

3

1 reference

19 September 2017

page(s)

360-369

1 reference

Novel therapies for recurrent ovarian cancer management

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

Immunotherapy opportunities in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

A systematic overview of chemotherapy effects in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

Interleukin-12 in anti-tumor immunity and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

Interleukin-12-mediated tumoricidal activity of patient lymphocytes in an autologous in vitro ovarian cancer assay system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

Antitumoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer: implications for the use of ovarian cancer biopsy-derived fibroblasts as a vehicle for regional gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

Intraperitoneal chemotherapy as primary treatment of advanced ovarian cancer: efficacy, toxicity, and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

Percutaneous placement of peritoneal port-catheter in oncologic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

7 January 2021

Immunoregulation by interleukin-12.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

7 January 2021

Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

7 January 2021

Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

7 January 2021

The role of CXC chemokines as regulators of angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

7 January 2021

Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

7 January 2021

Interleukin-12 requires initial CD80-mediated T-cell activation to support immune responses toward human breast and ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

7 January 2021

Effects of IL-12 on human ovarian tumors engrafted into SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

7 January 2021

Interleukin-12-gene transduction makes DCs from tumor-bearing mice an effective inducer of tumor-specific immunity in a peritoneal dissemination model

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

7 January 2021

https://api.crossref.org/works/10.1038%2FGT.2009.159

1 reference

7 January 2021

Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

7 January 2021

Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2009.159

7 January 2021

Identifiers

DOI

10.1038/GT.2009.159

1 reference

Dimensions Publication ID

19 September 2017

1015741647

0 references

1 reference